Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

NCT05626101 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Non-muscle-invasive Bladder Cancer

Interventions

DRUG: BCG
DRUG: Gemcitabine

Sponsor

Al-Azhar University